HORMONES, HORMONE RECEPTORS, AND AGING--HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

激素、激素受体和衰老——更年期女性的激素替代

• 批准号: 2565669
• 负责人: S M HARMAN
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON AGING
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2565669
• 关键词: aging; blood lipid; body composition; bone density; bone metabolism; clinical research; drug adverse effect; estrogens; female; glucose metabolism; hormone regulation /control mechanism; hormone therapy; human old age (65+); human subject; human therapy evaluation; lipid metabolism; longitudinal human study; menopause; postmenopause; progestins; psychometrics; vasomotion; women's health

In a study of estrogen-progestin co-therapy in older women, 30 healthy women 65-75 years of age were treated for 2 years with Premarin and low dose daily Provera with 30 untreated age-matched BLSA women as controls. Rate of bone loss by DEXA, biochemical indices of bone turnover, plasma lipids, body composition by anthropometry and DEXA, vaginal maturation indices, and responses to questionnaires assessing clinical effects were measured. There were significant increases in bone mineral density which correlated with decreases in biomarkers of bone resorption, as well as significant decreases in total and LDL cholesterol and increases in HDL cholesterol. There were also decreases in depression, anger, and tension as measured by the Profile of Mood Scale and significant decreases in vasomotor symptoms. Frequent adverse effects included breast swelling and tenderness and vaginal spotting. The positive effects on bone, lipids, and affect with minimal adverse effects, suggest that older women should be included in future randomized clinical trials of estrogen use. In a study assessing the longitudinal changes in hormone regulation, bone and mineral metabolism, and glucose and lipid metabolism in healthy women during the menopausal transition, 90 women have completed a total of 465 GCRC outpatient visits. Preliminary analyses suggest that accelerated bone loss may occur prior to the cessation of menses. A sufficient number of outpatient study visits have been performed to warrant longitudinal data analyses comparing the endocrine profiles to the bone biochemistries, bone density measurements, and body composition assessments. These analyses are underway.

在一项对老年女性进行雌激素和孕激素联合治疗的研究中，30名健康女性 65-75岁的女性使用倍美力和Low治疗2年 30名年龄匹配的BLSA妇女每日服用普罗维拉 控制。用双能X线骨密度仪测定骨丢失率、骨生化指标 周转，血脂，人体测量和DXA的身体成分， 阴道成熟指数，以及对问卷评估的反应 观察两组临床疗效。骨骼显著增加。 骨密度与骨生物标志物下降的相关性 吸收，以及总胆固醇和低密度脂蛋白的显著下降 以及高密度脂蛋白胆固醇的增加。抑郁症的发病率也有所下降， 愤怒，和紧张，通过心境量表和 血管舒缩症状显著减少。频繁的不良反应 包括乳房肿胀、压痛和阴道斑。这个 对骨骼、血脂和影响有积极作用，不良反应最小， 建议将老年妇女纳入未来的随机临床试验 雌激素使用的试验。在一项评估纵向变化的研究中 激素调节、骨骼和矿物质代谢以及葡萄糖和脂肪 90例绝经过渡期健康女性的代谢研究 共完成465次GCRC门诊就诊。初步分析 提示加速的骨丢失可能发生在停止 月经。已经有足够数量的门诊研究访问 以保证对内分泌进行纵向数据分析 骨生物化学、骨密度测量和身体概况 作文评估。这些分析正在进行中。